Arrhythmias pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

July 2020 | 72 pages | ID: ABAA7C6FA7F3EN
VPAResearch

Abstracts

2020 Arrhythmias PIPELINE HIGHLIGHTS
Arrhythmias is one of the widely researched conditions during 2020 with 15 companies actively focusing on realizing pipeline’s potential. Development of Arrhythmias medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Arrhythmias market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Arrhythmias.

Good progress is anticipated during 2020 and 2021 with Arrhythmias pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Arrhythmias pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
Arrhythmias DRUG DEVELOPMENT PIPELINE OVERVIEW
The “Arrhythmias pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Arrhythmias pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Arrhythmias presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Arrhythmias pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Arrhythmias DRUG PROFILES
Arrhythmias development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-

• Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
• Phase of development
• Mechanism of Action
• Route of Administration
• Companies involved including originator, licensing companies, developer, investors, and others
• New molecular entity details
• Orphan drug designation and other special status provided by regulators

Arrhythmias COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Arrhythmias drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Arrhythmias. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 15 Arrhythmias companies including company overview, key snapshot, contact information, and their strategies on accelerating Arrhythmias pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- Academic Pharmaceuticals Inc, Aetas Pharma Co Ltd, Armgo Pharma Inc, BlueRock Therapeutics, Cardurion Pharmaceuticals LLC, Cynata Therapeutics Ltd, Espero BioPharma Inc, Galectin Therapeutics Inc, Gilead Sciences Inc, LATITUDE Pharmaceuticals Inc, LQT Therapeutics Inc, MimeTech Srl, Numerate Inc, OMEICOS Therapeutics GmbH, SignPath Pharma Inc

REASONS TO BUY

• The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
• This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
• Buyers can identify most promising drug candidates for treatment of Arrhythmias
• It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
• Users can estimate possible delays in the delivery of pipeline or launch of new products
• Stay ahead of competition through understanding their pipeline progression, strategies and outlook
• The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
• Optimize your licensing and technology transfer strategies through identification of prospect partners

Contents

1. INTRODUCTION TO ARRHYTHMIAS

1.1 Arrhythmias- Disease overview
1.2 Arrhythmias- Market Size
1.3 Arrhythmias- Companies Involved

2. ARRHYTHMIAS PIPELINE SNAPSHOT- 2020

2.1 Arrhythmias Pipeline by Phase
2.2 Arrhythmias Pipeline by Mechanism of Action
2.3 Arrhythmias Pipeline by Route of Administration
2.4 Arrhythmias Pipeline- New Molecular Entities
2.5 Arrhythmias Pipeline- Orphan Drug Designation/ Special Designation

3. ARRHYTHMIAS DRUG PROFILES

3.1 Current Status
3.2 Arrhythmias Drug Snapshot
3.3 Arrhythmias Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 Academic Pharmaceuticals Inc Arrhythmias Pipeline Insights and Clinical Trials
4.2 Aetas Pharma Co Ltd Arrhythmias Pipeline Insights and Clinical Trials
4.3 Armgo Pharma Inc Arrhythmias Pipeline Insights and Clinical Trials
4.4 BlueRock Therapeutics Arrhythmias Pipeline Insights and Clinical Trials
4.5 Cardurion Pharmaceuticals LLC Arrhythmias Pipeline Insights and Clinical Trials
4.6 Cynata Therapeutics Ltd Arrhythmias Pipeline Insights and Clinical Trials
4.7 Espero BioPharma Inc Arrhythmias Pipeline Insights and Clinical Trials
4.8 Galectin Therapeutics Inc Arrhythmias Pipeline Insights and Clinical Trials
4.9 Gilead Sciences Inc Arrhythmias Pipeline Insights and Clinical Trials
4.10 LATITUDE Pharmaceuticals Inc Arrhythmias Pipeline Insights and Clinical Trials
4.11 LQT Therapeutics Inc Arrhythmias Pipeline Insights and Clinical Trials
4.12 MimeTech Srl Arrhythmias Pipeline Insights and Clinical Trials
4.13 Numerate Inc Arrhythmias Pipeline Insights and Clinical Trials
4.14 OMEICOS Therapeutics GmbH Arrhythmias Pipeline Insights and Clinical Trials
4.15 SignPath Pharma Inc Arrhythmias Pipeline Insights and Clinical Trials

5. ARRHYTHMIAS MARKET NEWS AND UPDATES

6. APPENDIX

6.1 Sources and Methodology
6.2 Contact Information